JP2024537827A5 - - Google Patents

Info

Publication number
JP2024537827A5
JP2024537827A5 JP2024519822A JP2024519822A JP2024537827A5 JP 2024537827 A5 JP2024537827 A5 JP 2024537827A5 JP 2024519822 A JP2024519822 A JP 2024519822A JP 2024519822 A JP2024519822 A JP 2024519822A JP 2024537827 A5 JP2024537827 A5 JP 2024537827A5
Authority
JP
Japan
Prior art keywords
antigen
chain variable
variable region
binding polypeptide
specifically binds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024519822A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537827A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077203 external-priority patent/WO2023056315A1/en
Publication of JP2024537827A publication Critical patent/JP2024537827A/ja
Publication of JP2024537827A5 publication Critical patent/JP2024537827A5/ja
Pending legal-status Critical Current

Links

JP2024519822A 2021-09-29 2022-09-28 抗原結合ポリペプチド、抗原結合ポリペプチド複合体、及びhivにおけるそれらの使用方法 Pending JP2024537827A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163249722P 2021-09-29 2021-09-29
US63/249,722 2021-09-29
PCT/US2022/077203 WO2023056315A1 (en) 2021-09-29 2022-09-28 Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof in hiv

Publications (2)

Publication Number Publication Date
JP2024537827A JP2024537827A (ja) 2024-10-16
JP2024537827A5 true JP2024537827A5 (cg-RX-API-DMAC7.html) 2026-01-20

Family

ID=85783606

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024519822A Pending JP2024537827A (ja) 2021-09-29 2022-09-28 抗原結合ポリペプチド、抗原結合ポリペプチド複合体、及びhivにおけるそれらの使用方法

Country Status (13)

Country Link
US (1) US20250197481A1 (cg-RX-API-DMAC7.html)
EP (1) EP4408892A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024537827A (cg-RX-API-DMAC7.html)
KR (1) KR20240099226A9 (cg-RX-API-DMAC7.html)
CN (1) CN118660907A (cg-RX-API-DMAC7.html)
AR (1) AR127176A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022357501A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232365A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024000890A1 (cg-RX-API-DMAC7.html)
IL (1) IL311762A (cg-RX-API-DMAC7.html)
MX (1) MX2024003804A (cg-RX-API-DMAC7.html)
TW (1) TW202325744A (cg-RX-API-DMAC7.html)
WO (1) WO2023056315A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN116574748B (zh) * 2023-07-10 2023-09-12 昆明医科大学 一种用于靶向KRAS高频突变肿瘤的嵌合型nTCR-T构建方法
WO2025162460A1 (zh) * 2024-02-04 2025-08-07 南通壹宸生物医药科技有限公司 一种轭合化合物及其制备和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI622597B (zh) * 2011-03-28 2018-05-01 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
JP6407726B2 (ja) * 2012-03-01 2018-10-24 アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH 長寿命ポリペプチド結合分子
US9458244B2 (en) * 2012-12-28 2016-10-04 Abbvie Inc. Single chain multivalent binding protein compositions and methods
ES2894304T3 (es) * 2015-10-25 2022-02-14 Sanofi Sa Proteínas de unión triespecíficas y/o trivalentes para la prevención o tratamiento de infección por VIH
EP3443006B1 (en) * 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
WO2018075564A1 (en) * 2016-10-17 2018-04-26 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
US12365722B2 (en) * 2018-10-19 2025-07-22 University Of Maryland, College Park Multispecific antibodies targeting multiple epitopes on the HIV-1 envelope
EP4578507A3 (en) * 2018-11-01 2025-11-12 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
TW202104274A (zh) * 2019-04-09 2021-02-01 法商賽諾菲公司 用於治療hiv感染之三特異性及/或三價結合蛋白
EP4397748A4 (en) * 2021-08-30 2025-09-17 Kanglin Biotechnology Hangzhou Co Ltd GENE SEQUENCE CONSTRUCTION FOR GENE THERAPY AGAINST HIV INFECTION

Similar Documents

Publication Publication Date Title
JP7328267B2 (ja) Hiv感染症の予防または処置のための三重特異性および/または三価結合タンパク質
US10654943B2 (en) Tri-specific antibodies for HIV therapy
CA3232364A1 (en) Antigen binding polypeptides, antigen binding polypeptide complexes and methods of use thereof
RU2019108429A (ru) Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
JP2024501539A5 (cg-RX-API-DMAC7.html)
JP7676316B2 (ja) Hiv感染症の処置のためのクロスオーバー二重可変ドメイン(codv)フォーマットを使用した三重特異性および/または三価結合性タンパク質
JP2021521781A5 (cg-RX-API-DMAC7.html)
US20250197481A1 (en) Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIV
BR112020023432A2 (pt) molécula de ligação a gp41, composição farmacêutica e método para tratar ou prevenir infecção por hiv-1 em um indivíduo que precisa do mesmo
IL318098A (en) IGE-FCER pushers
RU2025133788A (ru) Нацеленные слитые белки на основе интерферона альфа и способы их применения
WO2025054730A1 (en) Hiv-1-targeted multabody constructs, compositions, and methods
RU2025101354A (ru) Мутант, способствующий гомологичному спариванию тяжелых и легких цепей мультиспецифичного антитела
RU2023100643A (ru) Антитела, связывающиеся с cd3 и folr1
NZ779814B2 (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
RU2023135060A (ru) Антитела, связывающиеся с cd3
RU2020130794A (ru) Антитело к gipr и его слитый с glp-1 белок, а также фармацевтическая композиция на его основе и его применение
NZ779814A (en) Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
RU2022104485A (ru) Антитела, связывающиеся с gprc5d
NZ779858B2 (en) Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use
RU2019134227A (ru) Биспецифические антитела, специфически связывающиеся с pd1 и lag3
NZ779858A (en) Bispecific anti-human a-beta/human transferrin receptor antibodies and methods of use